Companies
CanSino Biologics
continues advancing its proprietary mRNA vaccine platform, reporting Phase II safety and immunogenicity data for its CS-2034 mRNA vaccine in Chinese adults, building on its earlier position as a global pioneer of adenoviral-vector vaccines.
- Country
- China
mrna-platform
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | RMB 1,059.4 million (2025-12-31) | hkexnews.hk |
| Capacity | 100 million doses per year for mRNA facility in Shanghai (2023-02-20) | cansinotech.com |
| Production site | Tianjin and Shanghai, China; additional lines in Mexico, Pakistan, and Malaysia (2023-12-31) | cansinotech.com |
| Certification | GMP certificate from Malaysian NAPRA for meningococcal and pneumococcal vaccine facility (2026-03-30) | hkexnews.hk |
| Certification | Halal certification in Indonesia for Menhycia vaccine (2025-03-28) | cansinotech.com |
Independent sources: hkexnews.hk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Drug & vaccine development | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.